Effect of antiretroviral therapy in human immunodeficiency virus-infected children

Journal of the Medical Association of Thailand

Volumn 88, Issue SUPPL. 8, 2005, Pages

  Chearskul, Pimpanada ^a   Chokephaibulkit, Kulkanya ^a   Chearskul, Sanay ^a   Phongsamart, Wanatpreeya ^a   Plipat, Nottasorn ^a   Lapphra, Keswadee ^a   Vanprapar, Nirun ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Antiretroviral therapy; HAART; HIV infected children; Survival

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADOLESCENT; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; IMMUNE DYSREGULATION; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MONOTHERAPY; RASH; SIDE EFFECT; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HUMANS; INFANT; MALE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 31744447601     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
2. de Martino M, Tovo PA, Balducci M, Galli L, Gabiano C, Rezza G, et al. Reduction in mortality with the availability of antiretroviral therapy for children with perinatal HIV-1 infection. JAMA 2000;284:190-7.
3. Granados J, Amador J, de Miguel, et al. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children. Pediatr Infect Dis J 2003;22863-7.
4. Center of Disease Control and Prevention. Guidelines for the using of antiretroviral agents among HIV-infected adults and adolescents. MMWR 2002;51:1-55.
5. Antiretroviral therapy and medical management of pediatric HIV infection. Working group on antiretroviral therapy and medical management of infants, children and adolescents with HIV infection. Pediatrics 2000;102:4.
6. Kaplan JE, Hanson DL, Cohn DL, Karon J, Buskin S, Thompson M, et al. When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte count <350 cells/ L. Clin Infect Dis 2003;37:951-8.
7. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002;360:119-39.
8. Mofenson LM, Korelitz J, Meyer III WA, Bethel J, Rich K, Pahwa S, et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and longterm mortality risk in HIV-infected children. J Infect Dis 1997;175:1029-38.
9. Working group on antiretroviral therapy: National pediatric HIV resource center. Antiretroviral therapy and medical management of human immunodeficiency virus-infected child. Pediatr Infect Dis J 1993;12:512-22.
10. Yeni PG, Hammer Sm, Carpenter CCJ, Cooper DA, Fischl MA, Gatell JM, et al. Antiretroviral treatment for adult HIV infection in 2002: Updated recommendations for the International AIDS society-USA panel. JAMA 2002;288:222-35.
11. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001 Nov 28;286(20):2568-77.
12. Sterling TR, Chaisson RE, Moore RD. HIV-1 RNA, CD4 T-lymphocytes and clinical response to highly active antiretroviral therapy. AIDS 2001;152:251-7.
13. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection: November 30, 2004. (http://AIDSinfo.nih.gov,/ guidelines/pediatric/PED_032405.pdf, access April 20, 2005).
14. Sharland M, di Zub GC, Ramos JT, Blanche S, Gibb DM; PENTA Steering Committee. PENTA guidelines for the use of antiretroviral therapy in paediatric HIV infection. Pediatric European Network for Treatment of AIDS. HIV Med 2002 Jul;3(3):215-26.
15. World Health Organization. Scaling up antiretroviral therapy in resource-constrained settings: treatment guidelines for a public health approach. 2003 revision (http://www.who.int/hiv/pub/prev_care/en/ arvrevision2003en.pdf.pdf, access March 19, 2005).
16. Ministry of Public Health. Guidelines for antiretroviral treatment in children. In: Guidelines for the clinical management of HIV infection in children/adults. Nonthaburi. 2002;75-84.
17. Center for Disease Control and Prevention. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994;43:1-10.
18. Leonard E, McComsey G. Metabolic complications of antiretroviral therapy in children. Pediatr Infect Dis J 2003;22:77-84.
19. Johnston AM, Valentine ME, Ottinger J, Baydo R, Gryszowka V, Vavro C, et al. Immune reconstitution in human immunodeficiency virus-infected children receiving highly active antiretroviral S229 therapy: a cohort study. Pediatr Infect Dis J 2001 Oct;20:941-6.
20. Essajee SM, Kim M, Gonzalez C, Rigaud M, Kaul A, Chandwani S, et al. Immunologic and virologic responses to HAART in severely immunocompromised HIV-1-infected children. AIDS 1999 Dec 24;13:2523-32.
21. Cohen Stuart JW, Slieker WA, Rijkers GT, Noest A, Boucher CA, Suur MH, et al. Early recovery of CD4+ T lymphocytes in children on highly active antiretroviral therapy. AIDS 1998;12:2155-9.
22. Rossum A, Fraaij P, de Groot. Efficacy of highly active antiretroviral therapy in HIV-infected children. Lancet Infectious Diseases 2002;2:93-102.
23. McKinney RE, Johnson GM, Stanley K, Yong FH, Keller A, O'Donnell KJ, et al. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomativ therapy-naive HIV-1 infection. The Pediatrics AIDS Clinical Trials Group Prorocol 300 Study Team. J Pediatr 1998;133:500-8.
24. Pediatric European Network for Treatment of AIDS (PENTA). A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. AIDS 1998;12:F151-60.
25. Nachman S, Stanley K, Yogev R, Nachman SA, Stanley K, Yogev R, et al. Nucleoside analogues plus ritronavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized control trial. Pediatric AIDS Clinical Trials Group 338 Study Team. JAMA 2000;283:492-8.
26. Luzuriaga K, Bryson Y, Krogstad P, Robinson J, Stechenberg B, Lamson M, et al. Combination treatment with zidovudine, didanosine and nevirapine in infants with human immunodeficiency virus type 1 infection. N Engl J Med 1997;336:1343-9.
27. Yogev R, Lee S, Wiznia A, Yogev R, Lee S, Wiznia A, et al.; Pediatrics AIDS Clinical Trials Group 338 Study Team. Stavudine, nevirapine and ritronavir in stable antiretroviral therapy-experience children with human immunodeficiency virus infection. Pediatr Infect Dis J 2002;21:119-25.
28. Sanchez JM, Ramos Amador JT, Fernandez de Miguel S, et al. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children. Pediatr Infect Dis J 2003;22:863-7.
29. Oleske J. Review of recent guidelines for antiretroviral treatment of HIV-infected children. Top HIV Med 2003;11:180-4.
30. Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C, et al. Randomized placebo controlled trial of ritronavir in advanced HIV-1 disease. Lancet 1998;351:543-49.
31. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeters or less. N Eng J Med 1997;337:725-33.
32. Yazdanpanah Y, Sissoko D, Egger M, Mouton Y, Zwahlen M, Chene G. Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect comparison of controlled trials. BMJ 2004;328:249.
33. Ghani AC, Henley WE, Donnelly CA, Mayer S, Anderson RM. Comparison of the effectiveness of non-nucleoside reverse transcriptase inhibitor-containing and protease inhibitor-containing regimens using observational databases. AIDS 2001; 15:1133-1142.
34. Paediratric European Network for Treatment of AIDS (PENTA). Comparison of dual nucleoside-analogue reverse-transcriptase inhibiter regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomized trial. Lancet 2002;359:733-40.
35. Mueller BU, Nelson RP Jr, Sleasman J, Mueller BU, Sleasman J, Nelson RP Jr, et al. A phase I/II study of the protease inhibitor ritronavir in children with human immunodeficiency virus infection. Pediatrics 1998;101:335-43.
36. Krogstad P, Lee S, JohnsonG, Krogstad P, Lee S, Johnson G, et al. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritronavir for pretreated children infected with human immunodeficiency virus type 1. Clin Infect Dis 2002;34:991-1001.
37. Van Leeuwen R, Katlama C, Murphy RL, Squires K, Gatell J, Horban A, et al. A randomizes trial to study first line combination therapy with or without protease inhibitor in HIV-infected patients. AIDS 2003;17:987-99.
38. Staszewski S, Morales-Ramirez J, Tashima KT, Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults, Study 006 Team. N Engl J Med 1999;341:1865-73.
39. Robbins GK, De Gruttola V, Shafer RW, Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drugs regimens as initial therapy for HIV-1 infection. N Engl J Med 2003;349:2293-303.
40. Cozzi-Lepri A, Phillips AN, d'Arminio Monforte A, Cozzi-Lepri A, Phillips AN, d'Arminio Monforte A, et al. Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with two nucleoside analogues in Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study. J Infect Dis 2002;185:1062-9.
41. Matthews GV, Sabin CA, Mandalia S, Matthews GV, Sabin CA, Mandalia S, et al. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naïve patients: a cohort study. AIDS 2002;16:53-61.
42. Phillips AN, Pradier C, Lazzarin A, Phillips AN, Pradier C, Lazzarin A, et al. Viral load of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. AIDS 2001;15:2385-95.
43. Eshleman SH, Mracna M, Guay LA, Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in woman and infants receiving nevirapine to prevent HIV-1 vertical transmission ( HIVNET 012 ). AIDS 2001;15:1951-7.